Reported Earlier, GSK's Mocertatug Rezetecan Achieves 62% Response Rate In Platinum-Resistant Ovarian Cancer And 67% In Endometrial Cancer In Phase 1 BEHOLD-1 Trial

Benzinga Newsdesk www.benzinga.com Positive 94.7%

Neg 0% Neu 0% Pos 94.7%

Comments

No comments yet. Be the first!